Lv5
1110 积分 2026-03-19 加入
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
8天前
已完结
OA10.04 Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients
10天前
已完结
Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations
14天前
已完结
Antibody–drug conjugates for cancer
21天前
已完结
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy
23天前
已完结
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies
1个月前
已完结
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology
1个月前
已完结
Antibody–drug conjugates for cancer
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
皖公网安备34019202002308
